Glaukos GKOS
United StatesHealthcare · Medical DevicesUSD
198.69 USD (+15.4%)
13 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Glaukos Corporation is a medical technology company that develops and commercializes minimally invasive devices and therapies for the treatment of glaucoma, a leading cause of blindness.
Key points
from its scores- ✓Strong growth10.0
- ✓Good share-price trend9.8
- ✓Favourable backdrop7.7
- ✕Demanding valuation0.5
- ✕Little or no dividend1.5
AI analysis
bottom line, main risk, context and newsHold only for investors with high risk tolerance and a very long-term horizon; profitability and deleveraging are the key metrics to watch.
Glaukos shows explosive revenue growth of 49.5%, but from a non-profitable base (operating margin of -8.49%) and with a highly leveraged balance sheet (Net Debt/EBITDA of 4.82), which, combined with an extremely demanding valuation (forward P/E of 328.86), presents a high-risk profile.
The main risk is the combination of high financial leverage (ND/EBITDA of 4.82) with negative operating profitability, which could lead to solvency issues if revenue growth decelerates or interest rates continue to rise.
Context and risks
The main risk is company-specific: its high leverage and lack of profitability.
Is Glaukos stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 385% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 14.8 | 4.1 | +261% |
| Price / sales | 16.6 | 3.4 | +385% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.5 out of 10 (median for Healthcare: 4.7).
Average analyst target: 198.69 USD, +15.4% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 3.3 (sector 5.5), Growth 10.0 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 328.9
- EV / EBITDA
- −269.3
- Price / book
- 14.8
- Price / sales
- 16.6
- Market cap
- 10.2B USD
- Enterprise value
- 10.0B USD
Profitability
- ROE
- −26.0%
- ROA
- −5.2%
- ROIC (approx.)
- −6.6%
- Gross margin
- 79.1%
- Operating margin
- −8.5%
- Net margin
- −30.7%
- Free cash flow
- 15.5M USD
- FCF yield
- 0.2%
Solvency
- Total debt
- 107.6M USD
- Net debt
- −178.6M USD
- Cash
- 286.2M USD
- EBITDA
- −37.0M USD
- Net debt / EBITDA
- 4.82
- Debt / equity
- 15.77
- Current ratio
- 5.04
- Quick ratio
- 4.16
Growth
- Revenue growth
- +49.5%
- EPS (TTM)
- −3.26 USD
- EPS (forward)
- 0.52 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.69
- Analyst consensus
- Strong buy (13)
- Target price
- 198.69 USD
- 52-week range
- 73.16 – 191.62
Recent news
All GKOS news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Glaukos
Is Glaukos stock cheap or expensive?
On Price / sales, it trades 385% above the Healthcare median. Valuation score: 0.5 out of 10 (median for Healthcare: 4.7). Average analyst target: 198.69 USD, +15.4% versus the price. This is not investment advice.
What score does Glaukos get on MeridIAn Screener?
It scores 4.5 out of 10, rank 1,875 of 2,130 (better than 11% of the companies analysed). Its strongest category is Growth (10.0) and its weakest, Valuation (0.5). Analysis of 08/10/2026.
How much is Glaukos worth on the stock market?
Its market capitalisation is 10.2B USD and its enterprise value, debt included, is 10.0B USD.
How much debt does Glaukos have?
It has more cash than debt: net cash of 178.6M USD.
Does Glaukos pay a dividend?
It pays no dividend, or almost none.
How has Glaukos stock performed over the last year?
It has risen 108.6% over the last year, excluding dividends. Over the last 52 weeks it has traded between 73.16 and 191.62 USD. Past performance does not guarantee future results.
What do analysts think of Glaukos?
13 analysts cover it; their average recommendation is “Strong buy” and their average target is 198.69 USD (+15.4% versus the price). It is an estimate, not market data.